Lisinopril
Generic name: lisinopril · Brand names: Prinivil, Qbrelis, Zestril
Quick facts
Drug class
Value
angiotensin converting enzyme (ACE) inhibitor
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b, Highlights, Indications and Usage; also Description: 'Lisinopril is an oral long-acting angiotensin converting enzyme (ACE) inhibitor.'
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Rx or otc
Rx (DailyMed product type; not stated in the label text read, so confirm)
Forms and strengths
- Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg (Highlights, Dosage Forms and Strengths)
- Lisinopril tablets USP are supplied as 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg tablets for oral administration. (11 Description)
Generic available
Value
Yes: this record is a generic label (Lupin, ANDA077321 per the label's Marketing Information)
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Common use one line
Treats high blood pressure, is an add-on for heart failure, and is used within 24 hours of a heart attack (Indications and Usage).
What it is used for
Lisinopril lowers blood pressure in adults and children 6 years of age and older. It also reduces signs and symptoms of systolic heart failure, and it is used to reduce the risk of death in stable patients within 24 hours of a heart attack.
Section
1 INDICATIONS AND USAGE
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Note
First sentence of each of 1.1, 1.2 and 1.3 only; the rest of 1.1 (benefit and management paragraphs) is omitted.
Source text (exact source wording)
1.1 Hypertension
Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure.
1.2 Heart Failure
Lisinopril tablet USP is indicated to reduce signs and symptoms of systolic heart failure [see CLINICAL STUDIES (14.2)].
1.3 Reduction of Mortality in Acute Myocardial Infarction
Lisinopril tablet USP is indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction.
Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure.
1.2 Heart Failure
Lisinopril tablet USP is indicated to reduce signs and symptoms of systolic heart failure [see CLINICAL STUDIES (14.2)].
1.3 Reduction of Mortality in Acute Myocardial Infarction
Lisinopril tablet USP is indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction.
How it works
Lisinopril blocks an enzyme (ACE) that makes angiotensin II, a substance that tightens blood vessels and triggers aldosterone. Less angiotensin II means blood vessels relax and blood pressure goes down.
Section
12.1 Mechanism of Action
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion.
Dosage: adults
Hypertension
Adults usually start at 10 mg once a day, or 5 mg once a day if also taking a diuretic. The usual range is 20 mg to 40 mg per day in a single daily dose. Doses up to 80 mg have been used but do not appear to give greater effect.
Section
2.1 Hypertension
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Initial Therapy in adults: The recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 20 mg to 40 mg per day administered in a single daily dose. Doses up to 80 mg have been used but do not appear to give greater effect.
Use with Diuretics in Adults
If blood pressure is not controlled with lisinopril alone, a low dose of a diuretic may be added (e.g, hydrochlorothiazide, 12.5 mg). After the addition of a diuretic, it may be possible to reduce the dose of lisinopril.
The recommended starting dose in adult patients with hypertension taking diuretics is 5 mg once per day.
Use with Diuretics in Adults
If blood pressure is not controlled with lisinopril alone, a low dose of a diuretic may be added (e.g, hydrochlorothiazide, 12.5 mg). After the addition of a diuretic, it may be possible to reduce the dose of lisinopril.
The recommended starting dose in adult patients with hypertension taking diuretics is 5 mg once per day.
Heart failure
For heart failure the starting dose is 5 mg once daily, or 2.5 mg once daily if serum sodium is low (< 130 mEq/L). The dose can be raised as tolerated to a maximum of 40 mg once daily.
Section
2.2 Heart Failure
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
The recommended starting dose for lisinopril, when used with diuretics and (usually) digitalis as adjunctive therapy for systolic heart failure, is 5 mg once daily. The recommended starting dose in these patients with hyponatremia (serum sodium < 130 mEq/L) is 2.5 mg once daily. Increase as tolerated to a maximum of 40 mg once daily.
Acute mi
After a heart attack, start within 24 hours with 5 mg, then 5 mg after 24 hours, 10 mg after 48 hours, then 10 mg once daily for at least six weeks. Patients with a lower systolic blood pressure (≤ 120 mmHg and > 100 mmHg) start at 2.5 mg. If systolic pressure stays below 90 mmHg for more than 1 hour, the label says to withdraw lisinopril.
Section
2.3 Reduction of Mortality in Acute Myocardial Infarction
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
In hemodynamically stable patients within 24 hours of the onset of symptoms of acute myocardial infarction, give lisinopril tablets USP 5 mg orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily. Dosing should continue for at least six weeks.
Initiate therapy with 2.5 mg in patients with a low systolic blood pressure (≤ 120 mmHg and > 100 mm Hg) during the first 3 days after the infarct [see WARNINGS AND PRECAUTIONS (5.4)]. If hypotension occurs (systolic blood pressure ≤ 100 mmHg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure < 90 mmHg for more than 1 hour) lisinopril should be withdrawn.
Initiate therapy with 2.5 mg in patients with a low systolic blood pressure (≤ 120 mmHg and > 100 mm Hg) during the first 3 days after the infarct [see WARNINGS AND PRECAUTIONS (5.4)]. If hypotension occurs (systolic blood pressure ≤ 100 mmHg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure < 90 mmHg for more than 1 hour) lisinopril should be withdrawn.
Dosage: children
For children 6 years and older with glomerular filtration rate > 30 mL/min/1.73 m2 the starting dose is 0.07 mg per kg once daily (up to 5 mg total), adjusted up to 0.61 mg per kg (up to 40 mg) once daily. It is not recommended under 6 years or when glomerular filtration rate is < 30 mL/min/1.73 m2.
Section
2.1 Hypertension (Pediatric Patients 6 years of age and older with hypertension)
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
For pediatric patients with glomerular filtration rate > 30 mL/min/1.73m2, the recommended starting dose is 0.07 mg per kg once daily (up to 5 mg total). Dosage should be adjusted according to blood pressure response up to a maximum of 0.61 mg per kg (up to 40 mg) once daily. Doses above 0.61 mg per kg (or in excess of 40 mg) have not been studied in pediatric patients [see CLINICAL PHARMACOLOGY (12.3)].
Lisinopril tablet USP is not recommended in pediatric patients < 6 years or in pediatric patients with glomerular filtration rate < 30 mL/min/1.73m2[see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.1)].
Lisinopril tablet USP is not recommended in pediatric patients < 6 years or in pediatric patients with glomerular filtration rate < 30 mL/min/1.73m2[see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.1)].
Dosage adjustments
Drug interaction caps
The label gives no fixed dose cap for interactions. With diuretics it says to reduce the starting dose of lisinopril if the diuretic cannot be lowered or stopped, and to check potassium often with potassium-sparing diuretics.
Section
7.1 Diuretics
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Note
Full contiguous 7.1 text. The label gives no fixed dose cap; it says to reduce the starting dose of lisinopril tablets if the diuretic cannot be decreased or stopped.
Source text (exact source wording)
Initiation of lisinopril in patients on diuretics may result in excessive reduction of blood pressure. The possibility of hypotensive effects with lisinopril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If this is not possible, reduce the starting dose of lisinopril tablets [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.4)].
Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.
Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.
Kidney
No change is needed if creatinine clearance is > 30 mL/min. If creatinine clearance is ≥ 10 mL/min and ≤ 30 mL/min, the starting dose is half the usual (5 mg for hypertension, 2.5 mg for heart failure and for heart attack), raised as tolerated to a maximum of 40 mg daily. With hemodialysis or creatinine clearance < 10 mL/min the starting dose is 2.5 mg once daily.
Section
2.4 Dose in Patients with Renal Impairment
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
No dose adjustment of lisinopril is required in patients with creatinine clearance > 30 mL/min. In patients with creatinine clearance ≥ 10 mL/min and ≤ 30 mL/min, reduce the initial dose of lisinopril to half of the usual recommended dose i.e., hypertension, 5 mg; systolic heart failure, 2.5 mg and acute MI, 2.5 mg. Up titrate as tolerated to a maximum of 40 mg daily. For patients on hemodialysis or creatinine clearance < 10 mL/min, the recommended initial dose is 2.5 mg once daily [see USE IN SPECIFIC POPULATIONS (8.7) and CLINICAL PHARMACOLOGY (12.3)].
Liver
Note
No liver dose adjustment in the Lupin label. Label warns of hepatic failure (5.6).
Elderly
The label says no dose change is needed for older adults. In a heart attack study, 4.8% of patients aged 75 years and older stopped lisinopril because of kidney problems versus 1.3% of those younger than 75 years. Greater sensitivity in some older people cannot be ruled out.
Section
8.5 Geriatric Use
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
No dosage adjustment with lisinopril is necessary in elderly patients. In a clinical study of lisinopril in patients with myocardial infarctions (GISSI-3 Trial) 4,413 (47%) were 65 and over, while 1,656 (18%) were 75 and over. In this study, 4.8 % of patients aged 75 years and older discontinued lisinopril treatment because of renal dysfunction vs. 1.3% of patients younger than 75 years. No other differences in safety or effectiveness were observed between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Missed dose
Label
Note
No missed-dose text in the Lupin label (sections 1-17 read, including 17 Patient Counseling Information).
Medlineplus
Take it when you remember. If it is almost time for the next dose, skip the missed one. Do not take a double dose.
Section
What should I do if I forget a dose?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Source text (exact source wording)
Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Overdose
The most likely effect of an overdose is low blood pressure, usually treated with an intravenous saline infusion. Lisinopril can be removed by hemodialysis. In case of overdose call poison control at 1-800-222-1222.
Section
10 OVERDOSAGE
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Poison control
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Source text (exact source wording)
In case of overdose, call the poison control helpline at 1-800-222-1222. Symptoms of overdose may include the following: lightheadedness, fainting
Source text (exact source wording)
Following a single oral dose of 20 g/kg no lethality occurred in rats, and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.
Lisinopril can be removed by hemodialysis [see CLINICAL PHARMACOLOGY (12.3)].
Lisinopril can be removed by hemodialysis [see CLINICAL PHARMACOLOGY (12.3)].
Storage
Store at controlled room temperature, 20° to 25°C (68° to 77°F). Protect from moisture, freezing and excessive heat. Dispense in a tight container. This is the Lupin label; other labelers may differ.
Section
16 HOW SUPPLIED/STORAGE AND HANDLING (Storage)
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Note
Labeler-specific (Lupin). Section 16 captured verbatim with the UPDATE 3 slice method.
Source text (exact source wording)
Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Protect from moisture, freezing and excessive heat. Dispense in a tight container.
Boxed warning
If you become pregnant, stop lisinopril as soon as possible and call your doctor. Drugs like this can injure or kill a developing baby.
Section
BOXED WARNING
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
WARNING: FETAL TOXICITY
When pregnancy is detected, discontinue lisinopril as soon as possible [see WARNINGS AND PRECAUTIONS (5.1)] .
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see WARNINGS AND PRECAUTIONS (5.1)] .
When pregnancy is detected, discontinue lisinopril as soon as possible [see WARNINGS AND PRECAUTIONS (5.1)] .
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see WARNINGS AND PRECAUTIONS (5.1)] .
Contraindications
Do not use with a neprilysin inhibitor such as sacubitril, and not within 36 hours of switching to or from sacubitril/valsartan.
Section
4 CONTRAINDICATIONS
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Lisinopril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Lisinopril tablet USP within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see WARNINGS and PRECAUTIONS (5.2)].
Do not use if you have had angioedema or an allergic reaction to an ACE inhibitor before, or have hereditary or idiopathic angioedema.
Section
4 CONTRAINDICATIONS
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Lisinopril is contraindicated in patients with:
a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor
hereditary or idiopathic angioedema
a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor
hereditary or idiopathic angioedema
Do not use aliskiren with lisinopril if you have diabetes.
Section
4 CONTRAINDICATIONS
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Do not co-administer aliskiren with lisinopril in patients with diabetes [see DRUG INTERACTIONS (7.4)].
Warnings and precautions
Lisinopril can harm an unborn baby, especially in the second and third trimesters, and stopping it as soon as pregnancy is found is advised.
Section
5.1
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Heading
Fetal Toxicity
Source text (exact source wording)
Lisinopril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue lisinopril as soon as possible [see USE IN SPECIFIC POPULATIONS (8.1)].
Swelling of the face, lips, tongue or throat can happen at any time during treatment and can be fatal. Stop lisinopril promptly and get treatment.
Section
5.2
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Heading
Angioedema (head and neck)
Source text (exact source wording)
Angioedema of the face, extremities, lips, tongue, glottis and/or larynx, including some fatal reactions, have occurred in patients treated with angiotensin converting enzyme inhibitors, including lisinopril, at any time during treatment. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Lisinopril should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms of angioedema has occurred.
Swelling in the intestines can cause stomach pain with or without nausea or vomiting, and symptoms resolved after stopping the ACE inhibitor.
Section
5.2
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Heading
Angioedema (intestinal)
Source text (exact source wording)
Intestinal angioedema has occurred in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. In some cases, the angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor.
Kidney function should be checked from time to time. Some people, such as those with narrowed kidney arteries, chronic kidney disease, severe heart failure or low body fluid, are at higher risk of acute kidney failure.
Section
5.3
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Heading
Impaired Renal Function
Source text (exact source wording)
Monitor renal function periodically in patients treated with lisinopril. Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, post-myocardial infarction or volume depletion) may be at particular risk of developing acute renal failure on lisinopril. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on lisinopril [see ADVERSE REACTIONS (6.1), DRUG INTERACTIONS (7.4)].
Lisinopril can cause low blood pressure with symptoms. People with heart failure and systolic blood pressure below 100 mmHg, heart or brain blood vessel disease, low sodium, high dose diuretics, dialysis, or severe fluid or salt loss are at higher risk.
Section
5.4
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Heading
Hypotension
Source text (exact source wording)
Lisinopril can cause symptomatic hypotension, sometimes complicated by oliguria, progressive azotemia, acute renal failure or death. Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology.
Lisinopril can raise blood potassium, so it should be checked periodically. Kidney problems, diabetes, potassium-sparing diuretics, potassium supplements and potassium salt substitutes raise the risk.
Section
5.5
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Heading
Hyperkalemia
Source text (exact source wording)
Serum potassium should be monitored periodically in patients receiving lisinopril. Drugs that inhibit the renin angiotensin system can cause hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see DRUG INTERACTIONS (7.1)].
ACE inhibitors have been linked to a syndrome that starts with yellowing of the skin or eyes or liver inflammation and can progress to liver failure and sometimes death. Anyone who develops jaundice should stop the ACE inhibitor and get treatment.
Section
5.6
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Heading
Hepatic Failure
Source text (exact source wording)
ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant hepatic necrosis and sometimes death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical treatment.
Pregnancy and breastfeeding
Lisinopril can harm an unborn baby, so stop it as soon as pregnancy is found. No data are available on lisinopril in human milk. Because of the potential for severe reactions in a breastfed infant, the label advises women not to breastfeed during treatment.
Section
8.1 Pregnancy and 8.2 Lactation
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Note
First paragraph of 8.1 Risk Summary, then 8.2 Lactation Risk Summary, each verbatim; the 8.1 text between them (background risk, clinical considerations) is omitted.
Source text (exact source wording)
Lisinopril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue lisinopril as soon as possible.
8.2 Lactation
Risk Summary
No data are available regarding the presence of lisinopril in human milk or the effects of lisinopril on the breast fed infant or on milk production. Lisinopril is present in rat milk. Because of the potential for severe adverse reactions in the breastfed infant, advise women not to breastfeed during treatment with lisinopril.
8.2 Lactation
Risk Summary
No data are available regarding the presence of lisinopril in human milk or the effects of lisinopril on the breast fed infant or on milk production. Lisinopril is present in rat milk. Because of the potential for severe adverse reactions in the breastfed infant, advise women not to breastfeed during treatment with lisinopril.
Side effects
Common
The label's most common side effects (2% more often than placebo): with high blood pressure, headache, dizziness and cough; with heart failure, low blood pressure and chest pain; after a heart attack, low blood pressure.
Section
Highlights, Adverse Reactions; 6.1 Clinical Trials Experience
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Threshold
events 2% greater on lisinopril than on placebo
Note
Segments from 6.1 joined with '...' where intervening text is omitted.
Source text (exact source wording)
Common adverse reactions (events 2% greater than placebo) by use:
Hypertension: headache, dizziness and cough (6.1)
Heart Failure: hypotension and chest pain (6.1)
Acute Myocardial Infarction: hypotension (6.1)
[6.1 Clinical Trials Experience] The following adverse reactions (events 2% greater on lisinopril than on placebo) were observed with lisinopril alone: headache (by 3.8%), dizziness (by 3.5%), cough (by 2.5%). ... hypotension (by 3.8%), chest pain (by 2.1%). ... Patients treated with lisinopril had a higher incidence of hypotension (by 5.3%) and renal dysfunction (by 1.3%) compared with patients not taking lisinopril.
Hypertension: headache, dizziness and cough (6.1)
Heart Failure: hypotension and chest pain (6.1)
Acute Myocardial Infarction: hypotension (6.1)
[6.1 Clinical Trials Experience] The following adverse reactions (events 2% greater on lisinopril than on placebo) were observed with lisinopril alone: headache (by 3.8%), dizziness (by 3.5%), cough (by 2.5%). ... hypotension (by 3.8%), chest pain (by 2.1%). ... Patients treated with lisinopril had a higher incidence of hypotension (by 5.3%) and renal dysfunction (by 1.3%) compared with patients not taking lisinopril.
Less common
Other effects seen in 1% or more of patients include tiredness, weakness, orthostatic effects, constipation, flatulence, dry mouth, diarrhea, pancreatitis, gout and impotence. In a heart failure study of two dose levels (ATLAS), dizziness was 19% on the high dose versus 12% on the low dose.
Section
6.1 Clinical Trials Experience
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Note
Full contiguous 'Other clinical adverse reactions' list from 6.1. ATLAS heart-failure table (high dose n=1568 vs low dose n=1596): Dizziness 19% vs 12%; Hypotension 11% vs 7%; Creatinine increased 10% vs 7%; Hyperkalemia 6% vs 4%; Syncope 7% vs 5%.
Source text (exact source wording)
Other clinical adverse reactions occurring in 1 % or higher of patients with hypertension or heart failure treated with lisinopril in controlled clinical trials and do not appear in other sections of labeling are listed below:
Body as a whole:
Fatigue, asthenia, orthostatic effects.
Digestive:
Pancreatitis, constipation, flatulence, dry mouth, diarrhea.
Hematologic:
Rare cases of bone marrow depression, hemolytic anemia, leukopenia/neutropenia and thrombocytopenia.
Endocrine:
Diabetes mellitus, inappropriate antidiuretic hormone secretion.
Metabolic:
Gout.
Skin:
Urticaria, alopecia, photosensitivity, erythema, flushing, diaphoresis, cutaneous pseudolymphoma, toxic epidermal necrolysis, Stevens-Johnson syndrome, and pruritus.
Special Senses:
Visual loss, diplopia, blurred vision, tinnitus, photophobia, taste disturbances, olfactory disturbance.
Urogenital:
Impotence.
Miscellaneous:
A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, fever, vasculitis, eosinophilia, leukocytosis, paresthesia and vertigo. Rash, photosensitivity or other dermatological manifestations may occur alone or in combination with these symptoms.
Body as a whole:
Fatigue, asthenia, orthostatic effects.
Digestive:
Pancreatitis, constipation, flatulence, dry mouth, diarrhea.
Hematologic:
Rare cases of bone marrow depression, hemolytic anemia, leukopenia/neutropenia and thrombocytopenia.
Endocrine:
Diabetes mellitus, inappropriate antidiuretic hormone secretion.
Metabolic:
Gout.
Skin:
Urticaria, alopecia, photosensitivity, erythema, flushing, diaphoresis, cutaneous pseudolymphoma, toxic epidermal necrolysis, Stevens-Johnson syndrome, and pruritus.
Special Senses:
Visual loss, diplopia, blurred vision, tinnitus, photophobia, taste disturbances, olfactory disturbance.
Urogenital:
Impotence.
Miscellaneous:
A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, fever, vasculitis, eosinophilia, leukocytosis, paresthesia and vertigo. Rash, photosensitivity or other dermatological manifestations may occur alone or in combination with these symptoms.
Serious
Label
Serious effects in the label include swelling of the face and throat (angioedema), liver failure, low sodium, low blood sugar in people with diabetes taking diabetes medicine, mood changes, confusion and hallucinations.
Section
5.2, 5.6, 6.2 Post-marketing Experience
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Note
Joined fragments from three sections, labeled with '...'.
Source text (exact source wording)
Angioedema of the face, extremities, lips, tongue, glottis and/or larynx, including some fatal reactions, have occurred in patients treated with angiotensin converting enzyme inhibitors, including lisinopril, at any time during treatment. [5.2] ... ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant hepatic necrosis and sometimes death. [5.6] ... Post-marketing (6.2): Hyponatremia, cases of hypoglycemia in diabetic patients on oral antidiabetic agents or insulin; Mood alterations (including depressive symptoms), mental confusion, hallucinations; Psoriasis
Medlineplus
Call your doctor right away for swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles or lower legs, hoarseness, trouble breathing or swallowing, fever or sore throat or chills, yellowing of the skin or eyes, lightheadedness, fainting or chest pain.
Section
What side effects can this medication cause?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Source text (exact source wording)
Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately:
swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
hoarseness
difficulty breathing or swallowing
fever, sore throat, chills, and other signs of infection
yellowing of the skin or eyes
lightheadedness
fainting
chest pain
swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
hoarseness
difficulty breathing or swallowing
fever, sore throat, chills, and other signs of infection
yellowing of the skin or eyes
lightheadedness
fainting
chest pain
Led to discontinuation
In high blood pressure trials, 5.7% of patients on lisinopril stopped because of side effects. In heart failure patients treated for up to four years, 11% stopped. In 12-week controlled heart failure studies, 8.1% on lisinopril stopped versus 7.7% on placebo.
Section
6.1 Clinical Trials Experience
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Note
Hypertension paragraph and heart failure paragraph from 6.1 joined; the intervening sentence about adverse reactions 2% greater than placebo is omitted.
Source text (exact source wording)
In clinical trials in patients with hypertension treated with lisinopril, 5.7% of patients on lisinopril discontinued with adverse reactions.
In patients with systolic heart failure treated with lisinopril for up to four years, 11% discontinued therapy with adverse reactions. In controlled studies in patients with heart failure, therapy was discontinued in 8.1% of patients treated with lisinopril for 12 weeks, compared to 7.7% of patients treated with placebo for 12 weeks.
In patients with systolic heart failure treated with lisinopril for up to four years, 11% discontinued therapy with adverse reactions. In controlled studies in patients with heart failure, therapy was discontinued in 8.1% of patients treated with lisinopril for 12 weeks, compared to 7.7% of patients treated with placebo for 12 weeks.
Interactions
Drugs
Starting lisinopril while on a diuretic may drop blood pressure too much. Potassium-sparing diuretics can raise potassium, so potassium should be checked often.
Name
Diuretics
Section
7.1 Diuretics
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Initiation of lisinopril in patients on diuretics may result in excessive reduction of blood pressure. The possibility of hypotensive effects with lisinopril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If this is not possible, reduce the starting dose of lisinopril tablets [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.4)].
Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.
Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.
Taken with insulin or diabetes pills, lisinopril may lower blood sugar more and raise the risk of low blood sugar.
Name
Antidiabetics (insulins, oral hypoglycemic agents)
Section
7.2 Antidiabetics
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Concomitant administration of lisinopril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia.
NSAIDs can worsen kidney function in older, fluid-depleted or kidney-impaired patients and can weaken lisinopril's blood-pressure effect.
Name
NSAIDs including COX-2 inhibitors
Section
7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.
The antihypertensive effect of ACE inhibitors, including lisinopril, may be attenuated by NSAIDs.
The antihypertensive effect of ACE inhibitors, including lisinopril, may be attenuated by NSAIDs.
Combining lisinopril with an ARB, another ACE inhibitor or aliskiren raises the risk of low blood pressure, high potassium and kidney changes. Avoid combined use in general. Do not use aliskiren with lisinopril if you have diabetes, and avoid it with GFR <60 mL/min.
Name
Dual blockade of the renin-angiotensin system (ARBs, ACE inhibitors, aliskiren)
Section
7.4 Dual Blockade of the Renin-Angiotensin System (RAS)
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
The VA NEPHRON trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 ml/min), randomized them to lisinopril or placebo on a background of losartan therapy and followed them for a median of 2.2 years. Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.
In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on lisinopril and other agents that affect the RAS.
Do not co-administer aliskiren with lisinopril in patients with diabetes. Avoid use of aliskiren with lisinopril in patients with renal impairment (GFR <60 ml/min).
The VA NEPHRON trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 ml/min), randomized them to lisinopril or placebo on a background of losartan therapy and followed them for a median of 2.2 years. Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.
In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on lisinopril and other agents that affect the RAS.
Do not co-administer aliskiren with lisinopril in patients with diabetes. Avoid use of aliskiren with lisinopril in patients with renal impairment (GFR <60 ml/min).
Lithium toxicity has been reported with ACE inhibitors. Lithium levels should be monitored.
Name
Lithium
Section
7.5 Lithium
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs, which cause elimination of sodium, including ACE inhibitors. Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor. Monitor serum lithium levels during concurrent use.
Rarely, injectable gold with an ACE inhibitor has caused flushing, nausea, vomiting and low blood pressure.
Name
Gold (injectable)
Section
7.6 Gold
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including lisinopril.
These medicines may raise the risk of angioedema (swelling).
Name
mTOR inhibitors (temsirolimus, sirolimus, everolimus)
Section
7.7 mTOR Inhibitors
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema. [see WARNINGS AND PRECAUTIONS (5.2)].
Neprilysin inhibitors may raise the risk of angioedema. Use with sacubitril is contraindicated (see Contraindications).
Name
Neprilysin inhibitors (e.g., sacubitril)
Section
7.8 Neprilysin Inhibitor
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. [see WARNINGS and PRECAUTIONS (5.2)]
Food and alcohol
Name
Potassium salt substitutes (MedlinePlus)
Section
What special dietary instructions should I follow?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Source text (exact source wording)
Talk to your doctor before using salt substitutes containing potassium. If your doctor prescribes a low-salt or low-sodium diet, follow these directions carefully.
Patient tips
Label
Tell your doctor right away if you may be pregnant or become pregnant. Report swelling of the face, extremities, eyes, lips or tongue, or trouble swallowing or breathing, right away, and take no more drug until you have talked to your prescriber. Women should not breastfeed during treatment. Report light-headedness, especially in the first few days, and tell your prescriber if you faint. Sweating a lot, dehydration, vomiting or diarrhea can lower blood pressure. Do not use salt substitutes containing potassium without asking your doctor. If you have diabetes and take diabetes medicine or insulin, watch closely for low blood sugar, especially in the first month. Report signs of infection such as sore throat or fever.
Section
17 PATIENT COUNSELING INFORMATION
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Source text (exact source wording)
NOTE: This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
Pregnancy
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to notify their healthcare provider with a known or suspected pregnancy [see WARNINGS AND PRECAUTIONS (5.1) and USE IN SPECIFIC POPULATIONS (8.1)].
Angioedema
Angioedema, including laryngeal edema may occur at any time during treatment with angiotensin converting enzyme inhibitors, including lisinopril. Tell patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.
Lactation
Advise women not to breastfeed during treatment with lisinopril [see USE IN SPECIFIC POPULATIONS (8.2)].
Symptomatic Hypotension
Tell patients to report light-headedness especially during the first few days of therapy. If actual syncope occurs, tell the patient to discontinue the drug until they have consulted with the prescribing physician.
Tell patients that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; advise patients accordingly.
Hyperkalemia
Tell patients not to use salt substitutes containing potassium without consulting their physician.
Hypoglycemia
Tell diabetic patients treated with oral antidiabetic agents or insulin starting an ACE inhibitor to monitor for hypoglycaemia closely, especially during the first month of combined use [see DRUG INTERACTIONS (7.2)].
Leukopenia/Neutropenia
Tell patients to report promptly any indication of infection (e.g., sore throat, fever), which may be a sign of leukopenia/neutropenia.
Pregnancy
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to notify their healthcare provider with a known or suspected pregnancy [see WARNINGS AND PRECAUTIONS (5.1) and USE IN SPECIFIC POPULATIONS (8.1)].
Angioedema
Angioedema, including laryngeal edema may occur at any time during treatment with angiotensin converting enzyme inhibitors, including lisinopril. Tell patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.
Lactation
Advise women not to breastfeed during treatment with lisinopril [see USE IN SPECIFIC POPULATIONS (8.2)].
Symptomatic Hypotension
Tell patients to report light-headedness especially during the first few days of therapy. If actual syncope occurs, tell the patient to discontinue the drug until they have consulted with the prescribing physician.
Tell patients that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; advise patients accordingly.
Hyperkalemia
Tell patients not to use salt substitutes containing potassium without consulting their physician.
Hypoglycemia
Tell diabetic patients treated with oral antidiabetic agents or insulin starting an ACE inhibitor to monitor for hypoglycaemia closely, especially during the first month of combined use [see DRUG INTERACTIONS (7.2)].
Leukopenia/Neutropenia
Tell patients to report promptly any indication of infection (e.g., sore throat, fever), which may be a sign of leukopenia/neutropenia.
Medlineplus how to take
Take it by mouth, usually once a day, at the same time each day, exactly as prescribed. It controls but does not cure your condition. Keep taking it even if you feel well and do not stop without talking to your doctor.
Section
How should this medicine be used?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Source text (exact source wording)
Lisinopril comes as a tablet and a solution (liquid) to take by mouth. It is usually taken once a day. To help you remember to take lisinopril, take it around the same time every day. Take lisinopril exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Lisinopril controls your condition, but it is not a cure. Continue to take lisinopril even if you feel well. Do not stop taking lisinopril without talking to your doctor.
Lisinopril controls your condition, but it is not a cure. Continue to take lisinopril even if you feel well. Do not stop taking lisinopril without talking to your doctor.
Medlineplus precautions
Tell your doctor about aspirin, ibuprofen, naproxen and potassium supplements. Diarrhea, vomiting, not drinking enough fluids and heavy sweating can cause a drop in blood pressure with lightheadedness and fainting. Tell your surgeon or dentist you take lisinopril.
Section
What special precautions should I follow?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Source text (exact source wording)
the following nonprescription products may interact with lisinopril: aspirin and nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen (Advil, Motrin, others) and naproxen (Aleve); potassium supplements.
you should know that diarrhea, vomiting, not drinking enough fluids, and sweating a lot can cause a drop in blood pressure, which may cause lightheadedness and fainting.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking lisinopril.
you should know that diarrhea, vomiting, not drinking enough fluids, and sweating a lot can cause a drop in blood pressure, which may cause lightheadedness and fainting.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking lisinopril.
Medlineplus when to call
Call your doctor right away for swelling of the face or limbs, hoarseness, trouble breathing or swallowing, signs of infection, yellow skin or eyes, lightheadedness, fainting or chest pain. Have your blood pressure checked regularly.
Section
What side effects can this medication cause? / What other information should I know?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Source text (exact source wording)
If you experience any of these symptoms, call your doctor immediately: swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs; hoarseness; difficulty breathing or swallowing; fever, sore throat, chills, and other signs of infection; yellowing of the skin or eyes; lightheadedness; fainting; chest pain. Your blood pressure should be checked regularly to determine your response to lisinopril.
Reporting
FDA MedWatch: 1-800-FDA-1088. Poison control: 1-800-222-1222.
Alternatives
Class
angiotensin converting enzyme (ACE) inhibitor
Class source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b (Highlights Indications and Usage; 11 Description)
Class source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Openfda note
openFDA count of pharm_class_epc 'Angiotensin Converting Enzyme Inhibitor [EPC]' listed ramipril, captopril and trandolapril but did not list lisinopril, so that field was not used to confirm lisinopril's class.
Openfda url
https://api.fda.gov/drug/label.json?search=openfda.pharm_class_epc.exact:"Angiotensin Converting Enzyme Inhibitor [EPC]"&count=openfda.generic_name.exact&limit=15
Candidates
- ramipril
- captopril
- trandolapril
- enalapril
- benazepril
- fosinopril
- moexipril
- perindopril
- quinapril
Candidates source
openFDA list (ramipril, captopril, trandolapril) and MedlinePlus lisinopril page 'other ACE inhibitors' list (enalapril, benazepril, captopril, fosinopril, moexipril, perindopril, quinapril, ramipril, trandolapril)
Candidates source url
https://medlineplus.gov/druginfo/meds/a692051.html
Recommendation
none
Frequently asked questions
Question
What is lisinopril used for?
Answer
Lisinopril lowers blood pressure in adults and children 6 years of age and older, helps reduce signs and symptoms of systolic heart failure, and is used to reduce the risk of death in stable patients within 24 hours of a heart attack.
Source section
1 INDICATIONS AND USAGE
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Question
How should I take lisinopril?
Answer
MedlinePlus says to take it by mouth, usually once a day at the same time each day, exactly as prescribed.
Source section
How should this medicine be used?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Question
What should I do if I miss a dose?
Answer
MedlinePlus says take it when you remember. If it is almost time for the next dose, skip the missed one. Do not take a double dose.
Source section
What should I do if I forget a dose?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Question
Can I use salt substitutes or take ibuprofen with lisinopril?
Answer
Talk to your doctor before using salt substitutes that contain potassium (MedlinePlus). The label says NSAIDs can worsen kidney function in some patients and can weaken lisinopril's blood-pressure effect, and that potassium supplements and potassium-containing salt substitutes raise the risk of high potassium.
Source section
7.3 NSAIDs; 5.5 Hyperkalemia; MedlinePlus diet section
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Question
What are the most common side effects?
Answer
The label lists, for events 2% greater than placebo: headache, dizziness and cough in high blood pressure; low blood pressure and chest pain in heart failure; and low blood pressure after a heart attack.
Source section
6.1 Clinical Trials Experience
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Question
Is lisinopril safe in pregnancy or breastfeeding?
Answer
No. The boxed warning says to discontinue lisinopril as soon as possible when pregnancy is detected because these drugs can injure or kill a developing fetus. The label advises women not to breastfeed during treatment.
Source section
Boxed Warning; 8.1 Pregnancy; 8.2 Lactation
Source
DailyMed label, Lupin Pharmaceuticals, Inc. lisinopril tablets, set ID 7d6c31e2-b5a4-4279-8013-a8dad37ea73b
Source url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d6c31e2-b5a4-4279-8013-a8dad37ea73b&type=display
Question
When should I call a doctor right away?
Answer
MedlinePlus lists swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles or lower legs, hoarseness, trouble breathing or swallowing, fever or sore throat or chills, yellowing of the skin or eyes, lightheadedness, fainting and chest pain.
Source section
What side effects can this medication cause?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Question
Should I stop lisinopril when I feel well?
Answer
No. MedlinePlus says to keep taking it even if you feel well and not to stop without talking to your doctor, because it controls your condition but is not a cure.
Source section
How should this medicine be used?
Source
MedlinePlus
Source url
https://medlineplus.gov/druginfo/meds/a692051.html
Sources
- DailyMed lisinopril tablets, Lupin Pharmaceuticals, Inc.
Set id: 7d6c31e2-b5a4-4279-8013-a8dad37ea73b · Label effective or revised date: Revised: 10/2025 (Highlights); 'Revised: June 2024' also appears at the end of Section 17 · Dailymed version date: DailyMed list published_date Nov 17, 2025; final 'Revised: 10/2025' version line on the page · Fetched at: 2026-11-03 · Sections used: Boxed Warning, Sections 1-8, 10-14, 16 and 17 (all read: 50,000 characters via get_page_text plus section 16-17 via the slice method) - MedlinePlus Lisinopril
Label effective or revised date: Last Revised - 02/15/2021 · Fetched at: 2026-11-02 · Sections used: all patient sections - openFDA label endpoint (ACE inhibitor candidate list)
Fetched at: 2026-11-02 · Sections used: generic_name counts - DailyMed spls.json lisinopril list
Fetched at: 2026-11-03 · Sections used: all 4 pages (377 entries), pages 1-4 via page=1..4 - DailyMed Zestril label (brand), Upsher-Smith Laboratories, LLC
Set id: 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 · Label effective or revised date: Revised: 11/2024 · Fetched at: 2026-11-03 · Sections used: Revised line only - DailyMed lisinopril tablets, Chartwell RX, LLC (label-choice check)
Set id: 8824e5e5-ed35-4a95-bfd6-98a2e7c4bbce · Label effective or revised date: Revised: 6/2023 · Fetched at: 2026-11-03 · Sections used: Revised line only - DailyMed lisinopril tablets, Solco Healthcare U.S., LLC (label-choice check)
Set id: e299d477-a612-4af4-b6aa-f5addc8a736d · Label effective or revised date: Revised: 8/2024 · Fetched at: 2026-11-03 · Sections used: Revised line only - DailyMed lisinopril tablets, Camber Pharmaceuticals, Inc. (label-choice check)
Set id: 387068e7-7fb9-44f3-ae1c-e45ebc755a3e · Label effective or revised date: Revised: 8/2024 · Fetched at: 2026-11-03 · Sections used: Revised line only
Information is taken from the cited sources and is for general reference only. It is not medical advice. Report side effects to FDA MedWatch at 1-800-FDA-1088. For a poison emergency call 1-800-222-1222. See prices for this drug